2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Bioinformatics, Cell Expansion, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Biological Therapies, Bispecific Antibody Therapy, Immunotherapy, Artificial Intelligence (AI), Deep Learning, Biological Processes, Apoptosis, Pathogenesis, Genomics, Immune Mechanism, Metabolism, Microbiome, Molecular Biology, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Diseases, Immunology, Neutropenia, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Research, Fundamental Science, Translational Research, Clinical Research, Clinical Trials, Study Population, Human, Adult, Elderly
PAPER

3918 Iberdomide increases T cell functionality enhancing anti-BCMA CAR-T efficacy in multiple myeloma

Adolfo Aleman, PhD, Shriya Desai2, Sidorela Reci3, Kedwin Ventura4, Zachary M. Avigan, MD, MHS5, Rudra Prasad Dutta, PhD6, Leah Grossman, PhD7, Lauren Mc Mahon8, Neha Soni9, Alex Baturevych10, Melissa Works11, Jim Qin12, Ashwini Balakrishnan13, Michael Ports14, Alessandro Lagana, PhD15, Chad C Bjorklund, Ph.D.16, Michael Amatangelo, PhD17, Patrick Hagner18, Anita Gandhi, PhD19, Samir Parekh, MD20
1 Icahn School of Medicine at Mount Sinai, New York, New York, United States
2 Icahn School of Medicine at Mount Sinai, New York, New York, United States
3 Icahn School of Medicine at Mount Sinai, New York, New York, United States
4 Icahn School of Medicine at Mount Sinai, New York, New York, United States
5 Icahn School of Medicine at Mount Sinai, New York, New York, United States
6 Icahn School of Medicine at Mount Sinai, New York, New York, United States
7 Icahn School of Medicine at Mount Sinai, New York, New York, United States
8 Icahn School of Medicine at Mount Sinai, New York, New York, United States
9 Juno Therapeutics, a Bristol-Myers Squibb company, Seattle, Washington, United States
10 Juno Therapeutics, a Bristol-Myers Squibb company, Seattle, Washington, United States
11 Juno Therapeutics, a Bristol-Myers Squibb company, Seattle, Washington, United States
12 Juno Therapeutics, a Bristol-Myers Squibb company, Seattle, Washington, United States
13 Juno Therapeutics, a Bristol-Myers Squibb company, Seattle, Washington, United States
14 Juno Therapeutics, a Bristol-Myers Squibb company, Seattle, Washington, United States
15 Icahn School of Medicine at Mount Sinai, New York, New York, United States
16 Bristol-Myers Squibb, Summit, New Jersey, United States
17 Bristol-Myers Squibb, Summit, New Jersey, United States
18 Bristol-Myers Squibb, Summit, New Jersey, United States
19 Bristol-Myers Squibb, Summit, New Jersey, United States
20 Icahn School of Medicine at Mount Sinai, New York, New York, United States

Background: Anti-BCMA CAR-T therapy has yielded impressive durable responses in patients with RRMM, however, suboptimal CAR-T expansion and T cell exhaustion remain critical mechanisms of resistance. Iberdomide (Iber), a CELMoD agent with potent T cell immunostimulatory effects, has been shown to reinvigorate the immune system and provide increased T cell functionality in patients. Synergistic combination of Iber and CAR-T therapy may therefore provide beneficial outcomes for patients. We investigated the impact of Iber in combination with CAR-T therapy and as a priming agent for improving T cell health prior to CAR-T manufacturing in preclinical models.

Methods: Anti-BCMA CAR-T cells were manufactured from T cells using lentiviral spinoculation, followed by standard expansion. To mimic potential clinical settings for Iber administration, it was evaluated as both an adjunctive agent concurrently with CAR-T and as a T cell priming agent prior to CAR-T manufacture. First, to examine Iber’s potential synergistic effects, CAR-T were treated with Iber or DMSO vehicle control for 24 hours to mimic direct combination and then assessed for phenotypic and functional changes. Iber’s effect on proliferation was identified through Ki-67 staining and growth curves. Activation and exhaustion profile was quantified using a custom spectral by flow cytometry panel. CAR-T functionality was investigated by implementing co-culture assays and quantifying antigen specific cytokine production as well as cytotoxicity against BCMA-expressing cell lines. To evaluate the role of concurrent Iber treatment in vivo, NSG mice were dosed with CAR-T cells and then given Iber daily or placebo. Second, to assess Iber’s potential for T cell priming, T cells were incubated with Iber prior to CAR-T manufacturing, and Iber primed CAR-T cells were then tested in vitro and in vivo. In vivo efficacy was evaluated in NSG mice engrafted intravenously with luciferase-expressing MM cells and treated on day 7 with a single infusion of either Iber primed produced CAR-T or unprimed CAR-T cells. In vivo tumor burden was tracked by serial bioluminescence imaging and survival analyzed by the Kaplan-Meier method with log-rank testing.

Results: Iber induced a near-complete degradation of transcriptional factors Ikaros and Aiolos in primary CAR-T cells without impairing viability, and it significantly increased T cell proliferation and expansion by day 7. The combination of Iber with CAR-T cells caused an upregulation of canonical activation markers such as CD25, CD69, and HLA-DR, and reduction of exhaustion markers TIGIT and PD1 (p<0.01). CAR-T cells combined with Iber produced more antigen specific TNF-α and IL-2, and they had significantly greater cytotoxicity, reflecting a shift toward an activated, pro-inflammatory phenotype. In vivo modeling demonstrated increased CAR-T proliferation seen with increased circulating CAR-T cells and enhanced tumor control in the CAR-T and Iber treated group (p<0.01).

Priming T cells prior to CAR-T manufacturing resulted in similar beneficial effects to CAR-T products. Iber primed anti-BCMA CAR-T cells expanded at a greater rate and phenotypically displayed lower exhaustion markers. Iber primed CAR-T cells increased functionality with greater in vitro cytotoxicity against MM cell lines and augmented cytokine production (p<0.01). Iber-primed CAR-T cells demonstrated superior in vivo anti-myeloma activity compared to DMSO-control CAR-T cells in NSG mice. Iber-primed CAR-T cells exhibited enhanced tumor control with sustained remission resulting in increased overall survival compared to DMSO-control CAR-T (median 85 vs 48 days, p<0.001).

Conclusions: Iber can be incorporated into various phases of CAR-T therapy to provide increased efficacy. Combinational therapy of CAR-T with Iber provides enhanced proliferation, functionality and tumor control. Priming patients T cells prior to apheresis and CAR-T expansion is another method that results in superior CAR-T products. An ongoing clinical trial at our institute evaluating one cycle of Iber prior to apheresis will prospectively determine whether this approach optimizes CAR-T product quality and improves outcomes. Taken together, our findings provide a mechanistic rationale for Iber-mediated CAR-T priming and support the clinical investigation of multiple Iber combinations with anti-BCMA CAR-T cell therapy to improve efficacy in patients with relapsed/refractory multiple myeloma.

Adolfo Aleman, PhD: No relevant conflicts of interest to declare.